Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate

Ewa Motta, Anna Gołba, Maciej Huć, Zofia Kazibutowska

Abstract

Some observations suggest that in some patients with multiple sclerosis demyelination may affect the central and peripheral nervous systems at the same time. The influence of immunomodulatory therapy on peripheral nervous system damage in these patients is still unknown. We present a 43-year-old male patient with multiple sclerosis diagnosed at the age of 35 in whom flaccid tetraparesis with dysaesthesia preceded by paraesthesias of four limbs occurred one year after starting glatiramer acetate. The course of peripheral nervous system disease and results of cerebrospinal fluid examination and electromyography confirmed Guillain-Barré syndrome. Interfering in the immunological system, glatiramer acetate may have contributed to the development of the symptoms of Guillain-Barré syndrome in our patient. The final improvement of the patient’s condition may have resulted not only from the applied treatment and the natural course of the disease, but may have also been associated with the discontinuation of glatiramer acetate.

Key words: Guillain-Barré syndrome, multiple sclerosis, glatiramer acetate.

Introduction

As early as in the second half of the 20th century, it was supposed that demyelination may affect the central and peripheral nervous systems at the same time. The proportion of multiple sclerosis (MS) patients in whom abnormalities in the electrophysiological examination of peripheral nerves were found varies considerably, from 5% to 74.2% [1-6]. In almost all the reports of changes in the examined peripheral nerves in MS patients, the da...
mage to those nerves was mostly demyelinating, and it was asymptomatic in most cases.

In the literature there are few cases of Guillain-Barré syndrome (GBS) occurring in patients with clinically definite MS [7]. In 2008, Sharma et al. [8] described five cases of chronic inflammatory demyelinating polyneuropathy (CIDP) which developed in MS patients. None of those patients was treated with interferon beta, so the possibility of inducing polyneuropathy by this drug was excluded. Ekstein et al. [2] described six cases of neuropathy caused by interferon beta in MS patients. Neuropathy receded in five patients after the discontinuation of this treatment, and the re-introduction of this drug caused the recurrence of neuropathy in two patients [2]. In the MS patients described by Pirko et al. [5], CIDP developed after 4 months, 1 year and 4 years, respectively from the beginning of treatment with interferon beta.

Case report

We report the case of a 43-year-old man with relapsing-remitting form of MS who developed Guillain-Barré syndrome after one year of treatment with glatiramer acetate. The patient was diagnosed with MS at the age of 35. The disease course was relapsing-remitting with approximately one exacerbation each other year. The patient met revised McDonald’s [9] criteria with both clinical presentation and additional examinations; magnetic resonance imaging of the brain showed multiple and mainly periventricular demyelinating lesions; visual evoked potentials were abnormal, cell count and protein level in cerebrospinal fluid were within the normal range. The patient was ambulatory with Expanded Disability Status Scale score of 2.0. Glatiramer acetate treatment was started in April 2007. In April 2008, the patient developed flaccid tetraparesis with lack of tendon reflexes (III/IV on Lovett scale) and polyneuropathic dyseaesthesias preceded by paraesthesias of calf and feet.

Over the following few days, symptoms worsened to bilateral facial paralysis and flaccid paralysis of the lower limbs. These symptoms coincided with a respiratory tract infection (right-sided pneumonia) confirmed by X-ray examination. The examination of the cerebrospinal fluid showed an increase in protein level (54 mg/dL) with cell count within the normal range. Electroneurographic examination showed signs of axonal demyelinating sensory motor neuropathy. Tests for ANA, dsDNA and anti-Borrelia antibodies were negative.

Neuroimaging examination of the head and the cervical spine did not show new active demyelinating lesions. The patient was diagnosed with Guillain-Barré syndrome. Treatment with glatiramer acetate was withdrawn. The patient received antibiotics and immunoglobulins at the dose of 0.4 mg/kg/day for five consecutive days. A significant improvement in the function of the limbs as well as a slight improvement of the electroneurographic parameters were achieved. Facial paresis persisted. The continued, several-month long rehabilitation of the patient brought further normalisation of the neurological condition and the electroneurographic findings.

Discussion

Glatiramer acetate consists of acetate salts of oligopeptides composed of four naturally occurring amino acids. Glatiramer acetate influences immune cells in an antigen-specific way. Administered chronically, it acts as an antigen-based therapeutic vaccine. Glatiramer acetate oligopeptides administered subcutaneously interact with antigen presenting cells and blood lymphocytes locally at the site of injection. The systemic immune response is mediated by circulating activated glatiramer acetate-reactive T cells. Glatiramer acetate-specific Th2 cells cross the blood-brain barrier and, accumulated in the CNS, release anti-inflammatory cytokines inhibiting nearby immune cells (bystander suppression mechanism) [10-13]. Additionally, these Th2 cells secrete neurotrophic substances (e.g. brain-derived neurotrophic factor) which might mediate suggested glatiramer acetate neuroprotective activity. All patients treated with glatiramer acetate develop specific antibodies against the drug which reach peak levels after 3-6 months of therapy and then stabilize at low levels. Glatiramer acetate oligopeptides also stimulate peripheral blood lymphocytes; the initial Th1 pro-inflammatory response with repeated administration of glatiramer acetate switches to the Th2 anti-inflammatory type [14].

We have not found a description of the occurrence of Guillain-Barré syndrome in an MS patient treated with glatiramer acetate. There was however a successful trial to treat experimental autoimmune neuritis (which is an experimental model of Guillain-Barré syndrome in mice) with glatiramer acetate [15]. The mechanism in which glatiramer acetate might have contributed to the development of Guillain-Barré syndrome in our patient is uncertain. Cross-reaction of peripheral nerve myelin antigens with glatiramer acetate-speci-
fic antibodies after one year of therapy is rather questionable. The patient suffered from pneumonia, which often precedes Guillain-Barré syndrome. It cannot be excluded that modulation of the immune system with glatiramer acetate treatment eased immunopathological processes which led to Guillain-Barré syndrome development. The improvement of the patient’s condition may have resulted not only from the applied treatment and the natural course of the disease, but may have also been associated with the discontinuation of glatiramer acetate. One thing is certain in this case: glatiramer acetate treatment did not prevent Guillain-Barré syndrome development in our patient.

Disclosure

Authors report no conflict of interest.

References